Form 6-K Evogene Ltd. For: Aug 05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of August 2015
Commission File Number: 001-36187
EVOGENE LTD.
(Translation of Registrant’s Name into English)
13 Gad Feinstein Street
Park Rehovot P.O.B 2100
Rehovot 7612002 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
CONTENTS
Attached hereto and incorporated by reference herein is the following exhibit:
|
99.1
|
Press Release: Evogene Reports Second Quarter 2015 Financial Results.
|
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: August 5, 2015
|
EVOGENE LTD.
(Registrant)
By: /s/ Sigal Fattal
——————————————
Sigal Fattal
Chief Financial Officer
|
3
EXHIBIT INDEX
|
EXHIBIT NO.
|
DESCRIPTION
|
|
99.1
|
Press Release: Evogene Reports Second Quarter 2015 Financial Results.
|
4
Exhibit 99.1
Evogene Reports Second Quarter 2015 Financial Results
Rehovot, Israel – August 5, 2015 – Evogene Ltd. (NYSE; TASE: EVGN), a leading company for the improvement of crop productivity and economics for the food and feed industries, announced today its financial results for the quarter and six months ended June 30, 2015.
Ofer Haviv, Evogene's President and CEO, stated: "These past few weeks have been extremely rewarding from the standpoint of Evogene’s on-going corporate growth and development. As we indicated at the time of our US IPO in late 2013, Evogene intended to allocate a large portion of the IPO proceeds towards new opportunities with substantial growth potential and a real need for innovation to drive the next generation of product development. This strategic undertaking, and the investment we made over the past year and a half in doing so, was well demonstrated by two milestone achievements that we recently disclosed.
“First, in our herbicide program, last month we announced the successful discovery and validation in plants of the first set of potential targets. These novel targets are a significant achievement for Evogene’s herbicide program, particularly since they are predicted to represent potential new 'mode of action', or manner, to kill weeds, and thus may provide the basis to the development of future weed-killing products."
“Second, we recently disclosed the successful completion of our first computational round of microbial genes in our insect control program, which was only initiated mid last year. This is a remarkable achievement considering that in a relatively short period of time we were able to leverage our knowhow and technology to tackle a new and commercially attractive market segment with significant barriers to innovation. This first set of promising genes provides us with strong confidence in the approach we are pursuing for the discovery of microbial genes, and more importantly in their likelihood to eventually yield a commercial product."
"In addition to the importance of these achievements for the programs themselves, they again demonstrate the power and broad applicability of our computational based predictive approach in the development of next-generation agriculture based products.”
Mr. Haviv concluded, “In summary, when looking across the various areas of the business, we are extremely excited with the initial progress we have made in advancing our newest areas of focus - insect control and novel herbicides - to the next stages of product development, and with our continued efforts in narrowing the gap to successful product introduction in our more established market areas.”
Financial results for the period ended June 30, 2015:
Cash Position: As of June 30, 2015, Evogene had $110 million in cash, short term bank deposits and marketable securities, representing a net cash usage of $6.3 million for the six months ended June 30, 2015.
Research Revenues include mainly periodic payments for research and development activities provided under certain of the Company's collaboration agreements with seed companies. Revenues from research and development payments for the six months ended June 30, 2015 were $5.3 million, compared to $7.5 million for the same period in 2014. Revenues from research and development payments for the second quarter of 2015 were $2.6 million, compared to $3.8 million for the same period in 2014. The decline was primarily related to the previously announced amendment to the Company’s Bayer collaboration work plan.
Evogene anticipates that longer term, its primary sources of revenues will be future royalties and other revenue sharing amounts, as well as castor seed sales by its wholly owned subsidiary Evofuel. In that regard, research revenues, which reflect R&D related cost reimbursement under certain of Evogene's collaboration agreements, were in the past a meaningful contributor to cash flow. Today, in consideration of the Company's strong cash balances, research revenues do not constitute a significant or essential part of the Company's cash flow.
Looking forward, Evogene intends to consider, on a case by case basis, self-financing certain activities under future collaborations. Although possibly resulting in less short term R&D revenues than would otherwise be the case, the Company’s goal in negotiating the terms for future collaborations will be to maximize long term revenues, consistent with maintaining its financial strength.
Cost of Revenues largely includes research and development expenses related to the support of the Company’s on-going activities under collaboration agreements with seed companies, which provide for future milestone and/or royalty revenues. Cost of revenues for the six months ended June 30, 2015 was $3.8 million, compared to $5.0 million, for the same period in 2014. Cost of revenues for the second quarter of 2015 was $1.9 million, compared to $2.4 million, for the same period in 2014.
Research and Development Expenses for the six months ended June 30, 2015 were $7.2 million, compared to $6.0 million for the same period in 2014. This increase largely relates to expansion of self-funded activities, primarily focused on the development of new computational genomics platforms and validation technologies, mainly in our key growth engines – insect resistance and ag-chemicals. The increase also derives from an increase in non-cash share-based compensation expenses. Research and Development Expenses for the second quarter of 2015 were $3.7 million, compared to $3.4 million for the same period in 2014. This increase mainly relates to increase in non-cash share-based compensation expenses. As stated above, research and development expenses do not include such expenses incurred in support of on-going collaborations, which are accounted for as Cost of Revenues.
- 2 -
Operating Loss for the six months ended June 30, 2015 was $8.8 million (including a non-cash expense of approximately $2.2 million for amortization of share-based compensation), compared to an operating loss of $6.4 million (including a non-cash expense of approximately $1.7 million for amortization of share-based compensation) for the same period in 2014. Operating Loss for the second quarter of 2015 was $4.6 million (including a non-cash expense of approximately $1.4 million for amortization of share-based compensation), compared to an operating loss of $3.7 million (including a non-cash expense of approximately $0.9 million for amortization of share-based compensation) for the same period in 2014. This increase is mainly attributable to the increase in self-funded research and development expenses, the increase in non-cash share-based compensation expenses and the decrease in revenues from research and development payments as described above.
Conference call and webcast details:
Evogene management will host a conference call today at 09:00 am Eastern time, 16:00 Israel time to discuss the results. US-based participants are invited to access the call by dialing 1-888-668-9141, and participants from Israel and other countries are invited to access the call at 972-3-918-0609. A replay of the conference call will be available beginning at approximately 13:00 Eastern time, 20:00 Israel time today, and will be accessible through August 7, 2015. US-based participants are invited to access the replay by dialing 1-888-782-4291, and participants from Israel and other countries are invited to access the replay at 972-3-925-5904. A replay of the call may also be accessed as a webcast via Evogene’s website at www.evogene.com and will be available for a period of ten days.
About Evogene Ltd.:
Evogene (NYSE, TASE: EVGN) is a leading company for the improvement of crop productivity and economics for the food and feed industries. The Company has strategic collaborations with world-leading agricultural companies to develop improved seed traits in relation to yield and a-biotic stress (such as tolerance to drought), and biotic stress (such as resistance to disease and nematodes), in key crops as corn, soybean, wheat and rice, and is also focused on the research and development of new products for crop protection (such as weed control). In addition, the Company has a wholly-owned subsidiary, Evofuel, developing seeds for second generation feedstock for biodiesel. For more information, please visit www.evogene.com.
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact:
Karen Mazor, Evogene
Director, Public and Investor Relations
T: (+972)-54-228-8039
- 3 -
CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
|
As of June 30,
|
As of
December 31,
|
|||||||||||
|
2015
|
2014
|
2014
|
||||||||||
|
Unaudited
|
Audited
|
|||||||||||
|
CURRENT ASSETS:
|
||||||||||||
|
Cash and cash equivalents
|
$ | 7,949 | $ | 8,716 | $ | 5,213 | ||||||
|
Restricted cash
|
- | - | 1,000 | |||||||||
|
Marketable securities
|
78,812 | 78,549 | 80,040 | |||||||||
|
Short-term bank deposits
|
23,228 | 24,000 | 30,046 | |||||||||
|
Trade receivables
|
750 | 1,864 | 1,183 | |||||||||
|
Other receivables
|
1,084 | 1,026 | 889 | |||||||||
| 111,823 | 114,155 | 118,371 | ||||||||||
|
LONG-TERM ASSETS:
|
||||||||||||
|
Long-term bank deposits
|
- | 10,000 | - | |||||||||
|
Long-term deposits
|
24 | 20 | 21 | |||||||||
|
Plant, property and equipment, net
|
8,016 | 7,188 | 8,812 | |||||||||
|
Long-term investment
|
- | 471 | 382 | |||||||||
|
Intangible assets, net
|
- | 22 | - | |||||||||
| 8,040 | 17,701 | 9,215 | ||||||||||
| $ | 119,863 | $ | 131,856 | $ | 127,586 | |||||||
|
CURRENT LIABILITIES:
|
||||||||||||
|
Trade payables
|
$ | 1,205 | $ | 1,488 | $ | 1,984 | ||||||
|
Other payables
|
2,485 | 2,840 | 3,854 | |||||||||
|
Liabilities in respect of grants from the Chief Scientist
|
553 | 603 | 570 | |||||||||
|
Deferred revenues and other advances
|
1,248 | 1,572 | 1,511 | |||||||||
| 5,491 | 6,503 | 7,919 | ||||||||||
|
LONG-TERM LIABILITIES:
|
||||||||||||
|
Liabilities in respect of grants from the Chief Scientist
|
3,145 | 2,939 | 3,103 | |||||||||
|
Deferred revenues and other advances
|
845 | 567 | 453 | |||||||||
|
Severance pay liability, net
|
28 | 19 | 29 | |||||||||
| 4,018 | 3,525 | 3,585 | ||||||||||
|
SHAREHOLDERS' EQUITY:
|
||||||||||||
|
Ordinary shares of NIS 0.02 par value:
Authorized - 150,000,000 ordinary shares; Issued and outstanding – 25,388,938, 25,010,394 and 25,350,954 shares at June 30, 2015 and 2014 and December 31, 2014, respectively
|
140 | 138 | 140 | |||||||||
|
Share premium and other capital reserve
|
177,962 | 172,077 | 175,553 | |||||||||
|
Accumulated other comprehensive loss
|
- | - | (222 | ) | ||||||||
|
Accumulated deficit
|
(67,748 | ) | (50,387 | ) | (59,389 | ) | ||||||
| 110,354 | 121,828 | 116,082 | ||||||||||
| $ | 119,863 | $ | 131,856 | $ | 127,586 | |||||||
- 4 -
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
U.S. dollars in thousands (except share and per share data)
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended December 31,
|
||||||||||||||||||
|
2015
|
2014
|
2015
|
2014
|
2014
|
||||||||||||||||
|
Unaudited
|
Audited
|
|||||||||||||||||||
|
Revenues:
|
||||||||||||||||||||
|
Research and development payments, including up-front payments
|
$ | 5,276 | $ | 7,542 | $ | 2,616 | $ | 3,767 | $ | 14,198 | ||||||||||
|
Share purchase related revenues
|
81 | 165 | 40 | 83 | 313 | |||||||||||||||
|
Total Revenues
|
5,357 | 7,707 | 2,656 | 3,850 | 14,511 | |||||||||||||||
|
Cost of revenues
|
3,762 | 4,988 | 1,932 | 2,425 | 9,709 | |||||||||||||||
|
Gross profit
|
1,595 | 2,719 | 724 | 1,425 | 4,802 | |||||||||||||||
|
Operating expenses:
|
||||||||||||||||||||
|
Research and development, net
|
7,229 | 6,012 | 3,690 | 3,355 | 14,022 | |||||||||||||||
|
Business development
|
999 | 936 | 502 | 562 | 1,851 | |||||||||||||||
|
General and administrative
|
2,137 | 2,124 | 1,174 | 1,236 | 4,185 | |||||||||||||||
|
Total operating expenses
|
10,365 | 9,072 | 5,366 | 5,153 | 20,058 | |||||||||||||||
|
Operating loss
|
(8,770 | ) | (6,353 | ) | (4,642 | ) | (3,728 | ) | (15,256 | ) | ||||||||||
|
Financing income
|
1,277 | 1,353 | 331 | 703 | 2,242 | |||||||||||||||
|
Financing expenses
|
(866 | ) | (528 | ) | (639 | ) | (166 | ) | (1,516 | ) | ||||||||||
|
Net loss
|
$ | (8,359 | ) | $ | (5,528 | ) | $ | (4,950 | ) | $ | (3,191 | ) | $ | (14,530 | ) | |||||
|
Other comprehensive loss:
|
||||||||||||||||||||
|
Gain (loss) from cash flow hedges
|
$ | (45 | ) | $ | - | $ | 19 | $ | - | $ | (222 | ) | ||||||||
|
Amounts transferred to the statement of profit or loss for cash flow hedges
|
267 | - | 72 | - | - | |||||||||||||||
|
Total comprehensive loss
|
$ | (8,137 | ) | $ | (5,528 | ) | $ | (4,859 | ) | $ | (3,191 | ) | $ | (14,752 | ) | |||||
|
Basic and diluted loss per share
|
$ | (0.33 | ) | $ | (0.22 | ) | $ | (0.20 | ) | $ | (0.13 | ) | $ | (0.58 | ) | |||||
- 5 -
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
U.S. dollars in thousands
|
Share
capital
|
Share Premium and other capital reserve
|
Accumulated other comprehensive loss
|
Accumulated Deficit
|
Total
|
||||||||||||||||
|
Unaudited
|
||||||||||||||||||||
|
Balance as of January 1, 2015 (audited)
|
$ | 140 | $ | 175,553 | $ | (222 | ) | $ | (59,389 | ) | $ | 116,082 | ||||||||
|
Net loss
|
- | - | - | (8,359 | ) | (8,359 | ) | |||||||||||||
|
Other comprehensive income
|
- | - | 222 | - | 222 | |||||||||||||||
|
Exercise of options
|
* | ) | 208 | - | - | 208 | ||||||||||||||
|
Share-based compensation
|
- | 2,201 | - | - | 2,201 | |||||||||||||||
|
Balance as of June 30, 2015
|
$ | 140 | $ | 177,962 | $ | - | $ | (67,748 | ) | $ | 110,354 | |||||||||
*) Represent amount lower than $1 thousand
|
Share
capital
|
Share Premium and other capital reserve
|
Accumulated Deficit
|
Total
|
|||||||||||||
|
Unaudited
|
||||||||||||||||
|
Balance as of January 1, 2014 (audited)
|
$ | 137 | $ | 169,469 | $ | (44,859 | ) | $ | 124,747 | |||||||
|
Total comprehensive loss
|
- | - | (5,528 | ) | (5,528 | ) | ||||||||||
|
Exercise of options
|
1 | 859 | - | 860 | ||||||||||||
|
Share-based compensation
|
- | 1,749 | - | 1,749 | ||||||||||||
|
Balance as of June 30, 2014
|
$ | 138 | $ | 172,077 | $ | (50,387 | ) | $ | 121,828 | |||||||
|
Share
capital
|
Share Premium and other capital reserve
|
Accumulated other comprehensive loss
|
Accumulated Deficit
|
Total
|
||||||||||||||||
|
unaudited
|
||||||||||||||||||||
|
Balance as of April 1, 2015
|
$ | 140 | $ | 176,437 | $ | (91 | ) | $ | (62,798 | ) | $ | 113,688 | ||||||||
|
Net loss
|
- | - | - | (4,950 | ) | (4,950 | ) | |||||||||||||
|
Other comprehensive income
|
- | - | 91 | - | 91 | |||||||||||||||
|
Exercise of options
|
* | ) | 134 | - | - | 134 | ||||||||||||||
|
Share-based compensation
|
- | 1,391 | - | - | 1,391 | |||||||||||||||
|
Balance as of June 30, 2015
|
$ | 140 | $ | 177,962 | $ | - | $ | (67,748 | ) | $ | 110,354 | |||||||||
*) Represent amount lower than $1 thousand
- 6 -
CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
U.S. dollars in thousands
|
Share
capital
|
Share Premium and other capital reserve
|
Accumulated Deficit
|
Total
|
|||||||||||||
|
Unaudited
|
||||||||||||||||
|
Balance as of April 1, 2014
|
$ | 138 | $ | 170,986 | $ | (47,196 | ) | $ | 123,928 | |||||||
|
Total comprehensive loss
|
- | - | (3,191 | ) | (3,191 | ) | ||||||||||
|
Exercise of options
|
* | ) | 168 | - | 168 | |||||||||||
|
Share-based compensation
|
- | 923 | - | 923 | ||||||||||||
|
Balance as of June 30, 2014
|
$ | 138 | $ | 172,077 | $ | (50,387 | ) | $ | 121,828 | |||||||
*) Represent amount lower than $1 thousand
|
Share
capital
|
Share Premium and other capital reserve
|
Accumulated other comprehensive loss
|
Accumulated Deficit
|
Total
|
||||||||||||||||
|
Audited
|
||||||||||||||||||||
|
Balance as of January 1, 2014
|
$ | 137 | $ | 169,469 | $ | - | $ | (44,859 | ) | $ | 124,747 | |||||||||
|
Net loss
|
- | - | - | (14,530 | ) | (14,530 | ) | |||||||||||||
|
Other comprehensive loss
|
- | - | (222 | ) | - | (222 | ) | |||||||||||||
|
Exercise of options
|
3 | 2,854 | - | - | 2,857 | |||||||||||||||
|
Share-based compensation
|
- | 3,230 | - | - | 3,230 | |||||||||||||||
|
Balance as of December 31, 2014
|
$ | 140 | $ | 175,553 | $ | (222 | ) | $ | (59,389 | ) | $ | 116,082 | ||||||||
- 7 -
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended December 31,
|
||||||||||||||||||
|
2015
|
2014
|
2015
|
2014
|
2014
|
||||||||||||||||
|
Unaudited
|
Audited
|
|||||||||||||||||||
|
Cash flows from operating activities
|
||||||||||||||||||||
|
Net loss
|
$ | (8,359 | ) | $ | (5,528 | ) | $ | (4,950 | ) | $ | (3,191 | ) | $ | (14,530 | ) | |||||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||||||||||||||
|
Adjustments to the profit or loss items:
|
||||||||||||||||||||
|
Depreciation and amortization
|
1,266 | 1,055 | 612 | 536 | 2,249 | |||||||||||||||
|
Share-based compensation
|
2,201 | 1,749 | 1,391 | 923 | 3,230 | |||||||||||||||
|
Net financing expenses (income)
|
(451 | ) | (12 | ) | 240 | (103 | ) | (926 | ) | |||||||||||
| 3,016 | 2,792 | 2,243 | 1,356 | 4,553 | ||||||||||||||||
|
Changes in asset and liability items:
|
||||||||||||||||||||
|
Decrease in trade receivables
|
433 | 49 | 66 | 12 | 730 | |||||||||||||||
|
Decrease (increase) in other receivables
|
(312 | ) | (293 | ) | (308 | ) | 5 | 58 | ||||||||||||
|
Decrease (increase) in long term deposits
|
(3 | ) | 8 | (4 | ) | 6 | 7 | |||||||||||||
|
Increase (decrease) in trade payables
|
(400 | ) | (606 | ) | (6 | ) | 14 | (267 | ) | |||||||||||
|
Increase (decrease) in other payables
|
(1,246 | ) | (1,523 | ) | 9 | (565 | ) | (895 | ) | |||||||||||
|
Increase (decrease) in severance pay liability, net
|
(1 | ) | - | 1 | - | 10 | ||||||||||||||
|
Increase (decrease) in deferred revenues
|
129 | (396 | ) | (401 | ) | 172 | (571 | ) | ||||||||||||
| (1,400 | ) | (2,761 | ) | (643 | ) | (356 | ) | (928 | ) | |||||||||||
|
Cash received during the period for:
|
||||||||||||||||||||
|
Interest received
|
1,372 | 226 | 551 | 143 | 2,010 | |||||||||||||||
|
Net cash used in operating activities
|
(5,371 | ) | (5,271 | ) | (2,799 | ) | (2,048 | ) | (8,895 | ) | ||||||||||
- 8 -
CONSOLIDATED STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
|
Six months ended
June 30,
|
Three months ended
June 30,
|
Year ended December 31,
|
||||||||||||||||||
|
2015
|
2014
|
2015
|
2014
|
2014
|
||||||||||||||||
|
Unaudited
|
Audited
|
|||||||||||||||||||
|
Cash flows from investing activities
|
||||||||||||||||||||
|
Purchase of property, plant and equipment
|
$ | (849 | ) | $ | (925 | ) | $ | (296 | ) | $ | (622 | ) | $ | (3,564 | ) | |||||
|
Proceeds from sale of marketable securities
|
14,854 | 8,096 | 7,016 | 3,759 | 31,195 | |||||||||||||||
|
Purchase of marketable securities
|
(13,905 | ) | (55,359 | ) | (7,424 | ) | (7,513 | ) | (80,615 | ) | ||||||||||
|
Proceeds from (investment in) bank deposits
|
6,818 | (34,000 | ) | (42 | ) | - | (30,046 | ) | ||||||||||||
|
Decrease (increase) in restricted cash
|
1,000 | - | 1,000 | - | (1,000 | ) | ||||||||||||||
|
Net cash provided by (used in) investing activities
|
7,918 | (82,188 | ) | 254 | (4,376 | ) | (84,030 | ) | ||||||||||||
|
Cash Flows from Financing Activities
|
||||||||||||||||||||
|
Proceeds from exercise of options
|
208 | 860 | 134 | 168 | 2,857 | |||||||||||||||
|
Proceeds from the Chief Scientist grants
|
188 | 126 | 188 | 126 | 339 | |||||||||||||||
|
Repayment of the Chief Scientist grants
|
(233 | ) | (272 | ) | - | - | (530 | ) | ||||||||||||
|
Net cash provided by financing activities
|
163 | 714 | 322 | 294 | 2,666 | |||||||||||||||
|
Exchange rate differences - cash and cash equivalent balances
|
26 | 7 | 106 | (12 | ) | 18 | ||||||||||||||
|
Increase (decrease) in cash and cash equivalents
|
2,736 | (86,738 | ) | (2,117 | ) | (6,142 | ) | (90,241 | ) | |||||||||||
|
Cash and cash equivalents, beginning of the period
|
5,213 | 95,454 | 10,066 | 14,858 | 95,454 | |||||||||||||||
|
Cash and cash equivalents, end of the period
|
$ | 7,949 | $ | 8,716 | $ | 7,949 | $ | 8,716 | $ | 5,213 | ||||||||||
|
Significant non-cash transactions
|
||||||||||||||||||||
|
Acquisition of property, plant and equipment
|
$ | 157 | $ | 379 | $ | 157 | $ | 379 | $ | 536 | ||||||||||
- 9 -